Search Results

The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers Cardarelli is a drug development leader with extensive experience driving drug discovery teams in bringing biology, pharmacology, translational medicine, oncology, immuno-oncology, immunology, and clinical development While at BMS and Medarex, she led programs from target ID to clinical development that included, CXCL10 including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic development

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Gebhard Schertler, he developed methods for kinetic mathematical analysis of GPCR signaling. Before focusing on the development of innovative mathematical modeling and simulation methods for drug Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery of interdisciplinary teamwork in drug and technology development, noting the challenges of communication

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

building GPCR research programs that translate fundamental discoveries into clinical impact and drug development discoveries worth pursuing to clinical endpoints, and navigating the pathway from academic research to drug development As co-founder and CEO of Keltic Pharma Therapeutics, he leads a biotechnology company developing a novel

Visit Website About Celtarys Research Celtarys Research develops and commercializes new chemical tools Her work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology Custom Development Customized fluorescent ligands developed in less than 3 months with optimal properties Custom Development Tailored fluorescent probes designed for unique research requirements.

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development and CEO of Phrenix Therapeutics, a biotech spin-out from the Neuromedicines Discovery Centre that is developing particularly in the field of psychiatry, where he has led multiple projects into late stage preclinical development

Raimond Heukers , developed a nanobody platform within the research group and used this platform to develop He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA

Khorana’s lab made early key contributions and developed strategies to express, reconstitute and assay He also went on to discover a “counterion switch” in visual pigments and to develop strategies to assay Tom’s lab also developed an amber codon suppression method to genetically encode unnatural amino acids Early applications included “targeted photo-crosslinking,” and more recently, the parallel development

Department, Ken Vecchio helping set the foundation for the Nanoengineering Materials Research Center and developing Scientists and Engineers working at the nanoscale, specifically protein engineering and small molecule drug development

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

Podcast , leaders from academia and biotech unpack what effective collaboration really looks like when developing The episode explores gpcr internalization , fluorescence-based probe design, and how functional assay development Listen This episode is for scientists and leaders who are: Navigating the transition from academic tool development co-founding the company in 2021, she has led all scientific activities, from proprietary technology development His research focuses on bottom-up chemical tool development for imaging and interrogating GPCRs and other

His team develops fluorescence-based and chemically engineered tools to study gpcr internalization and engagement in intact islets and neuronal circuits — insights that inform next-generation functional assay development His group develops imaging and chemical biology tools to reveal how GLP-1 and GIP receptors operate within

This was followed by a postdoctoral role at the Polytechnic University of Turin (Italy), where he developed Now in a tenure-track position, his research spans the development of computational methods such as structure-based

Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development I have participated and initiated methodologies for development of pharmacologically active anti-GPCR

has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

My project involved the development of FRET/BRET -based GPCR conformational biosensors, which can be I spent 2 1/2 years in his lab and developed novel conformational sensors for these intriguing receptors

identification of small molecule regulators of these proteins, and progressing such ligands in drug development non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing

Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development within the primary cilium, a tiny antenna-shaped structure at the cell surface with critical links to development Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford

full-length structures in multiple states still need to deliver for drug design 25:01 - Advice for early-career scientists: the role of passion in sustained scientific work 26:15 - Three "aha" moments that shaped a career

there — outcomes shaped as much by openness as by design — has followed him through every phase of his career Open a Pandora's Box Adhesion GPCRs appear across nearly every biological process — from embryonic development

She developed expertise over the past two decades studying structure/function relationships of GPCRs the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development Manager, where they managed a technical support team providing scientific data analysis and database development contributed analytic support resulting in authorship of numerous scientific publications and new funding, and developed delivered technical presentations and software demonstrations to prospective customers worldwide, and developed

This conversation is especially valuable for scientists developing functional assays, fluorescence-based lab structure at Monash Institute of Pharmaceutical Sciences fosters innovation in functional assay development Get behind-the-scenes conversations, advanced assay development strategies, and practical GPCR tools

receptors in cancer and metabolic diseases, and emerging high-throughput methods for functional assay development generation How computational approaches and wet-lab validation complement each other in functional assay development His current efforts bridge teaching in Toronto and ongoing research, including the development of an

He is the Research director at INSERM with a specific interest in G protein-coupled receptors by developing loss-of-function variants of the MT2 melatonin receptors that are associated with type 2 diabetes (TD2) development

Broichhagen reveals how fluorescent probes transform GPCR imaging, internalization studies, and assay development Balanced creativity in tool development with the pressure for reproducible, publication-grade data. research group at the Leibniz Research Institute for Molecular Pharmacology (FMP) in Berlin, focusing on developing

Organizers Eurofins DiscoverX Eurofins DiscoverX is a one-stop-shop for GPCR drug discovery and development scientists and biotech leaders working across pharmacology, translational research, and therapeutic development Curated intelligence on GPCR drug discovery trends and developments Expert-led webinars and masterclasses